JP2004506696A5 - - Google Patents

Download PDF

Info

Publication number
JP2004506696A5
JP2004506696A5 JP2002520853A JP2002520853A JP2004506696A5 JP 2004506696 A5 JP2004506696 A5 JP 2004506696A5 JP 2002520853 A JP2002520853 A JP 2002520853A JP 2002520853 A JP2002520853 A JP 2002520853A JP 2004506696 A5 JP2004506696 A5 JP 2004506696A5
Authority
JP
Japan
Prior art keywords
composition
receptor
neutralizing agent
biological response
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002520853A
Other languages
English (en)
Other versions
JP4864278B2 (ja
JP2004506696A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/025767 external-priority patent/WO2002015932A1/en
Publication of JP2004506696A publication Critical patent/JP2004506696A/ja
Publication of JP2004506696A5 publication Critical patent/JP2004506696A5/ja
Application granted granted Critical
Publication of JP4864278B2 publication Critical patent/JP4864278B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項1】 脱髄疾患に罹患した被験体における再有髄化を促進するための組成物であって、10kDaのインターフェロン誘導性タンパク質(IP−10)に特異的な有効量の中和剤を含む、組成物。
【請求項2】 前記被験体が哺乳動物である、請求項1に記載の組成物。
【請求項3】 前記被験体がヒトである、請求項2に記載の組成物。
【請求項4】 前記脱随疾患が多発性硬化症(MS)である、請求項1に記載の組成物。
【請求項5】 10kDaのインターフェロン誘導性タンパク質(IP−10)に特異的な前記中和剤が、抗IP−10抗体である、請求項1に記載の組成物。
【請求項】 IP−10に特異的な中和剤を同定する方法であって、候補中和剤の存在下でIP−10レセプターを発現する細胞をIP−10と接触させる工程、およびIP−10活性に関連する生物学的応答の発生を決定する工程を包含し、ここで、該生物学的応答の非発生によって、候補物質がIP−10中和剤として同定される、方法。
【請求項】 前記生物学的応答が、IP−10レセプターを発現する前記細胞の細胞内カルシウムレベルの変化である、請求項に記載の方法。
【請求項】 前記生物学的応答が、IP−10レセプターを発現する前記細胞の移動である、請求項に記載の方法。
【請求項】 前記レセプターがCXCR3レセプターである、請求項に記載の方法。
JP2002520853A 2000-08-18 2001-08-17 脱髄疾患を処置する方法 Expired - Fee Related JP4864278B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22639900P 2000-08-18 2000-08-18
US60/226,399 2000-08-18
PCT/US2001/025767 WO2002015932A1 (en) 2000-08-18 2001-08-17 Methods for treating demyelinating diseases

Publications (3)

Publication Number Publication Date
JP2004506696A JP2004506696A (ja) 2004-03-04
JP2004506696A5 true JP2004506696A5 (ja) 2008-12-25
JP4864278B2 JP4864278B2 (ja) 2012-02-01

Family

ID=22848755

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002520853A Expired - Fee Related JP4864278B2 (ja) 2000-08-18 2001-08-17 脱髄疾患を処置する方法

Country Status (7)

Country Link
EP (1) EP1317285B1 (ja)
JP (1) JP4864278B2 (ja)
AT (1) ATE444761T1 (ja)
AU (2) AU8828601A (ja)
CA (1) CA2420226C (ja)
DE (1) DE60140136D1 (ja)
WO (1) WO2002015932A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002316674B2 (en) * 2001-07-12 2007-09-13 The Regents Of The University Of California CXCL10 treatment of secondary tissue degeneration
AU2003294290A1 (en) 2002-11-15 2004-06-15 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
US8563476B2 (en) 2002-11-15 2013-10-22 Morehouse School Of Medicine Anti-CXCL9, anti-CXCL10, anti-CXCL11, anti-CXCL13, anti-CXCR3 and anti-CXCR5 agents for inflammatory disorders
WO2005060457A2 (en) * 2003-12-04 2005-07-07 Pdl Biopharma, Inc. Treatment of inflammatory bowel diseases with anti-ip-10 antibodies
ES2537163T3 (es) 2003-12-10 2015-06-03 E. R. Squibb & Sons, L.L.C. Anticuerpos de IP-10 y sus usos
AU2011250741B2 (en) * 2003-12-10 2014-04-03 E. R. Squibb & Sons, L.L.C. IP-10 antibodies and their uses
CA2678626A1 (en) 2007-02-28 2008-09-04 Novimmune S.A. Anti-ip-10 antibodies and methods of use thereof
CA2834552A1 (en) 2011-04-29 2012-11-01 Bristol-Myers Squibb Company Ip-10 antibody dosage escalation regimens
KR102630475B1 (ko) 2015-11-30 2024-01-26 브리스톨-마이어스 스큅 컴퍼니 항 인간 ip-10 항체 및 이의 용도
CN109475603B (zh) 2016-06-20 2023-06-13 科马布有限公司 抗pd-l1抗体
EP4338740A1 (en) 2022-09-13 2024-03-20 Johannes Gutenberg-Universität Mainz A transdermal patch for promoting or accelerating myelination and/or remyelination

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2259927A1 (en) * 1996-07-12 1998-01-22 Leukosite, Inc. Chemokine receptor antagonists and methods of use therefor
US6495569B1 (en) * 2001-04-19 2002-12-17 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
US20030166589A1 (en) * 2001-06-05 2003-09-04 Nathan Karin Method and pharmaceutical composition for the treatment of multiple sclerosis

Similar Documents

Publication Publication Date Title
HRP20201840T1 (hr) Postupci za ocjenjivanje imunološkog odgovora na terapijsko sredstvo
JP2004506696A5 (ja)
KR100237968B1 (ko) 변화된 에피토프를 지닌 단백질 및 그 제조방법
PL392311A1 (pl) Kompozycja farmaceutyczna hamująca ekspresję lub aktywność antygenu, sposób diagnozowania, sposób oznaczania regresji, sposób leczenia choroby, sposób hamowania rozwoju raka, kwas nukleinowy, cząsteczka zrekombinowanego DNA lub RNA, komórka gospodarza, białko lub polipeptyd, fragment immunologiczny białka lub polipeptydu, czynnik, przeciwciało, produkt sprzęgania, zestaw do wykrywania ekspresji i zrekombinowana cząsteczka
EP1064403A4 (en) ANTISENSE MODULATION OF PECAM-1
IL134142A0 (en) Catalytic monoclonal antibodies with protease activity for the selective lysis of the protein component of plaques and aggregates related to pathological conditions
EP2305715A3 (en) Monoclonal antibody to osteoprotegerin binding protein
JP2001511347A5 (ja)
DE60141844D1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
BR9806318A (pt) Polipeptìdeo pde8, polinucleotìdeo codificando o mesmo, dna, polinucleotìdeo anti-sentido, construção de expressão, célula hospedeira, processo para produzir um polipeptìdeo pde8, anticorpo, hibridoma, anticorpo anti-idiotipo, processo para identificar um composto parceiro de ligação espefcìfico de um polipeptìdeo pde8a, e de polinucleotìdeo pde8a, composto, e, composição.
MXPA02008239A (es) Gen humano de la esquizofrenia.
NO992472L (no) FremgangsmÕte for Õ diagnostisere metabolske bensykdommer
ATE368735T1 (de) Neue aggrecanase
CA2420226A1 (en) Methods for treating demyelinating diseases
ATE331786T1 (de) Matrix-metalloprotease
WO2001064876A3 (en) Human schizophrenia gene
ATE328080T1 (de) Proteine und für diese kodierende dna
ATE474627T1 (de) Einschritt-permanentkosmetikzusammensetzung
Orino et al. Characterization of bovine serum ferritin-binding proteins
ATE110469T1 (de) Nichttrennender festphasen-enzymtest.
EP0875760A3 (en) Elisa serodiagnosis of pig pleuropneumonia serotype 2
RU2005136389A (ru) Способ прогнозирования гестоза
WO2001088538A8 (en) Compositions and methods for epitope mapping
Laursen Fascioloides magna in Minnesota: Regional ecology of the fluke and serodiagnosis in cattle.
WO2005015990A8 (en) New diabetes type 2 animal model